Download the Complete Report Here By Rayk Riechmann Second quarter financial results are in for REX American Resources Corp. (NYSE: REX) and consistency is the word of the hour. Disciplined execution and strategic positioning mark REX a standout player in...

Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com  

CorpGov, IPO Edge and PE Edge will host the fifth annual Palm Beach CorpGov Forum on Wednesday, Nov. 5 and Thursday, Nov, 6, 2025, at the Palm Beach Lake Pavilion, located waterfront with sweeping views of Palm Beach Island. The Forum will...

By Karen Roman Vinson & Elkins said Ainsley Ierland joined its London’s finance practice as partner, following the addition of partner Harry Upcott to grow the firm’s global aviation finance platform in London, Dublin, and New York. Ms. Ierland’s experience focuses...

Tech Edge hosted a fireside chat on August 12 at Nasdaq MarketSite with Erik Carlson, President and Chief Executive Officer at Notified and James Cadwallader, Chief Executive Officer and Co-founder of Profound. The in-person interview was joined by Editor-in-Chief John...

Tech Edge hosted a fireside chat on August 12 at Nasdaq MarketSite with Erik Carlson, President and Chief Executive Officer at Notified and James Cadwallader, Chief Executive Officer and Co-founder of Profound. The in-person interview was joined by Editor-in-Chief John...

By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company’s Phase 2 trial...

CorpGov is pleased to announce the final agenda for the inaugural LA CorpGov Forum on Thursday, September 4, 2025, at 1500 N El Centro Ave, Los Angeles, California, in the heart of Hollywood. The forum will start at 2:00pm featuring...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG) said it received FDA and EMA clearance for GLORA-4, a global registrational Phase III trial of their Bcl-2 inhibitor lisaftoclax for first-line treatment of higher-risk myelodysplastic syndrome. The company said it is addressing...

Download the Complete Report Here By Rayk Riechmann With the final major citrus harvest finished in its third fiscal quarter, Alico, Inc. (Nasdaq: ALCO) completed a major strategic shift towards transforming into a diversified land management company. Finalizing this key...